Home Newsfeeds CJS Securities Downgrades John Wiley & Sons to Market Perform

CJS Securities Downgrades John Wiley & Sons to Market Perform

CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.

byBenzinga Newsdesk

August 29, 2022

1 minute read

CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.

News

Cisco And AT&T Join Forces To Help Businesses Expand Connectivity For A Growing Mobile-First Workforce

By Happy Mohamed

June 7, 11:41 AM

News Summary: Webex Calling is natively integrating with the AT&T mobile network to provide a powerful, mobile-first, and unified collaboration experience via a single business mobile number. AT&T and Cisco

CSCO

Mobileye’s Deal Wins Signal More Such Success Backed By Demand For SuperVision, Contributing To Higher Margins & FCF, Analysts Say

By Anusuya Lahiri

January 27, 2:20 PM

Needham analyst Rajvindra Gill maintained Mobileye Global Inc (NASDAQ:MBLY) with a Buy and raised the price target from $43 to $45. Mobileye’s…

MBLY

Lilly Shares Donanemab Data In First Active Comparator Study In Early Symptomatic Alzheimer’s Disease; Says Met All Primary, Secondary Endpoints

By Michael Horton

November 30, 7:02 PM

Eli Lilly and Company (NYSE:LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first active comparator

LLY

US Approves New Offshore Wind Project Offshore New York And New Jersey: Details

By Shivani Kumaresan

November 22, 11:35 AM

The United States Department of the Interior has given the green light to the Empire Wind offshore

CJS Securities Downgrades John Wiley & Sons to Market Perform

Related Posts

Cisco And AT&T Join Forces To Help Businesses Expand Connectivity For A Growing Mobile-First Workforce

Mobileye’s Deal Wins Signal More Such Success Backed By Demand For SuperVision, Contributing To Higher Margins & FCF, Analysts Say

Lilly Shares Donanemab Data In First Active Comparator Study In Early Symptomatic Alzheimer’s Disease; Says Met All Primary, Secondary Endpoints

US Approves New Offshore Wind Project Offshore New York And New Jersey: Details